Life sciences company Orexa has announced positive interim data for its Phase II trial evaluating ORE-001, a treatment for the prevention of post-operative ileus (POI) in patients undergoing major abdominal surgery. 

Interim analysis was conducted after 40 patients were randomised. The data demonstrated that ORE-001 could be a safe and effective treatment, with patients receiving ORE-001 consuming 63% more food compared to placebo, also showing a faster return of gastrointestinal function, reduced gastrointestinal dysfunction and staying in hospital for less time. 

Post-Operative Ileus (POI) is a prolonged absence of bowel function after surgical procedures, usually abdominal surgery. It is estimated that the economic impact of post-operative ileus is approximately $750 million annually in the US alone. 

The clinical trial for ORE-001, which is being conducted in Germany, is a multicentre, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of Orexa’s lead compound. 

“This is a remarkable outcome for a vulnerable patient population,” said Ard Peeters, CEO and Founder of Orexa. ”ORE-001 not only enhances patients wellbeing but also has the potential to substantially reduce healthcare costs through faster recovery and shorter hospital stays.”

“The early data from this study are clinically very meaningful and important,” added Alexander Mustea, Principal Investigator at Universitätsklinikum Bonn. ”ORE-001 has the potential to redefine how we manage post-operative recovery, particularly in high-risk surgical populations.”

Based on the interim results, Orexa will conclude the current Phase IIa study ahead of schedule and initiate preparations for Phase IIB/III studies to further evaluate ORE-001 in the same indication. 

 

Bruno Quinney, Content Team, DDW